Weight loss has always been big business, but it's exploded of late due to surging demand for Ozempic, Wegovy and other new diabetes and obesity drugs. "Whether you have five pounds to lose or 100, we want to make sure we're able to help everybody," Sharam Fouladgar-Mercer, Signos' co-founder and CEO, told CNBC in an interview. Fouladgar-Mercer said he created the company in 2018 partly because of his own struggle to manage weight throughout his life. Users can also integrate sleep data, heart rate data, and exercise data from their Apple Watch to personalize their profile even more. Fouladgar-Mercer said Signos can work well alongside Ozempic and Wegovy from Novo Nordisk and other GLP-1 treatments.

---

Persons: Signos, Mercer, it's, It's, GLP Organizations: Cheyenne Ventures, GV, Google Ventures, Dexcom Ventures, CNBC, Signos, U.S . Food, Drug Administration, Apple Watch, Abbott Laboratories, U.S, Novo Nordisk, Nordisk's Locations: Mercer, Novo, Europe, Fouladgar, America